Brought to you by 
AstraZeneca spins out Albireo
17 Feb 2021
Executive Summary
AstraZeneca PLC has spun out its gastrointestinal therapeutics business into a new company called Albireo Pharmaceutical. AZ, along with Nomura Phase4 Ventures, TVM Capital, and Scottish Widows Investment Partnership, provided $27mm in funding to the new entity in a Series A round that is expected to reach $40mm in the near future.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com